Guideline contact dermatitis

S1-Guidelines of the German Contact Allergy Group (DKG) of the German Dermatology Society (DDG), the Information Network of Dermatological Clinics (IVDK), the German Society for Allergology and Clinical Immunology (DGAKI), the Working Group for Occupational and Environmental Dermatology (ABD) of the DDG, the Medical Association of German Allergologists (AeDA), the Professional Association of German Dermatologists (BVDD) and the DDG

JOCHEN BRASCHE 1, DETLEF BECKER 2, WERNER ABERER 3, ANDREAS BIRCHER 4, BIRGER KRANKE 3, KIRSTEN JUNG 5, BERNHARD PRZYBILLA 6, TILO BIEDERMANN 7, THOMAS WERFEL 8, SWEN MALTE JOHN 9, PETER ELSNER 10, THOMAS DIEPGEN 11, AXEL TRAUTMANN 12, HANS F. MERK 13, THOMAS FUCHS 14, AXEL SCHNUCH 15

Preamble

Purpose of the guidelines

The present guidelines on contact dermatitis aim to provide orientation to physicians of all disciplines tasked with treating contact dermatitis patients. They are intended to describe recognized diagnostic, therapeutic, and interventional approaches on the basis of current understanding of contact dermatitis.

Separate guidelines have been developed for hand dermatitis [1].

Development and consensus-building procedures

The guidelines were developed in formal consensus of a group of experts (see authors) put together by the medical specialty societies active in the field of contact dermatitis in Germany. These include the German Contact Allergy Group (DKG) of the German Dermatology Society (DDG), the Information Network of Dermatological Clinics (IVDK), the German Society for Allergology and Clinical Immunology (DGAKI), the Working Group for Occupational and Environmental Dermatology (ABD) of the DDG, the Medical Association of German Allergologists (AeDA), the Professional Association of German Dermatologists (BVDD) and the DDG.

Cite this as

Brasch J, Becker D, Aberer W, Bircher A, Kränke B, Jung K, Przybilla B, Biedermann T, Werfel T, John SM, Elsner P, Diepgen T, Trautmann A, Merk HF, Fuchs T, Schnuch A. Guideline contact dermatitis: S1-Guidelines of the German Contact Allergy Group (DKG) of the German Dermatology Society (DDG), the Information Network of Dermatological Clinics (IVDK), the German Society for Allergology and Clinical Immunology (DGAKI), the Working Group for Occupational and Environmental Dermatology (ABD) of the DDG, the Medical Association of German Allergologists (AeDA), the Professional Association of German Dermatologists (BVDD) and the DDG. Allergo J Int 2014; 23: 126–38

DOI 10.1007/s40629-014-0013-5
man Dermatology Society (DDG; Aberer, Kränke, Becker, Bircher, Brasch), the Information Network of Dermatological Clinics (IVDK; Schnuch, Aberer, Brasch), the German Society for Allergology and Clinical Immunology (DGAKI; Przybilla, Biedermann, Werfel), the Working Group for Occupational and Environmental Dermatology (ABD) of the DDG (John, Elsner, Diepgen), the Medical Association of German Allergologists (AeDA; Merk, Fuchs), the Professional Association of German Dermatologists (BVDD; Jung) and the DDG (Trautmann).

Taking the previous version of the guidelines [2] as a basis, the first author developed an initial draft updated in terms of formal structure and content. Additions and modifications were then made in the context of an email discussion involving all authors, until a general consensus among the authors was reached.

Taking into account German-language and PubMed medical specialist journals, the authors systematically evaluated the scientific literature on the topic of contact dermatitis. However, the authors’ clinical experience was also taken into consideration. This decision seemed justified given that treatment approaches for contact dermatitis have been in use for decades and will continue to form the mainstay of clinical routine in spite of the fact that no efficacy studies according to currently valid criteria (double-blind, prospective, randomized) have been performed to date. Thus, disregarding empirical knowledge of this kind would have resulted in inadequate recommendations.

Limitations
These S1 guidelines were developed by the authors to the best of their knowledge and belief. However, the treating physician should review the adoption of these recommendations in each individual case, since deviations from recommended approaches may be necessary on the basis of individual circumstances. Studies in the future may also suggest alternative approaches.

Definition of contact dermatitis
An eczematous reaction is an inflammatory intolerance response characterized by successive and coexistent erythema, blisters, exudation, papules, and flaking. The term “dermatitis” is generally used as a synonym for “eczema”. This response pattern is caused primarily by toxins that have an external, non-infectious, immunological, chemical, or physical effect. This is classically the case in contact dermatitis. However, eczematous skin reactions can also be triggered via endogenous pathways or by systemic allergen intake.

From an etiological perspective, a distinction is made between allergic – generally delayed type (type IV) and only rarely immediate type (type I), as in protein contact dermatitis – and irritant (non-allergic) forms of contact dermatitis. Allergic forms presuppose sensitization to the offending allergen or a cross-reactive allergen. Irrespective of the varying etiology (type IV or type I allergy or skin irritation), a form of dermatitis develops. The irritant forms are also classified as toxic, degenerative, subtoxic, or cumulatively toxic. Many patients exhibit a combination of irritant and allergic mechanisms with an often synergistic effect [3].

Clinical symptoms alone often do not permit classification of the dermatitis as allergic or irritant contact dermatitis.

Acute, subacute, and chronic presentations can be distinguished according to morphology, development over time, and time of exposure to the toxin. This classification is also important for the choice of therapy.

Epidemiology
Allergen-specific (contact) sensitization is an essential precondition of allergic contact dermatitis. The prevalence of sensitization to individual contact allergens varies widely in Germany, Austria, and German-speaking areas of Switzerland according to patient populations, is partially occupation-related, and subject to special analyses and surveillance [4, 5, 6]. However, it is not possible to draw conclusions about the frequency of contact dermatitis directly from the prevalence of sensitization to contact allergens. The relevance of irritants as the potential causal agents of irritant contact dermatitis has been extensively investigated, particularly in certain occupational groups [7]. The likelihood of developing irritant contact dermatitis rises with the intensity and duration of exposure to the irritant. Depending on the occupational field investigated, irritant or allergic contact dermatitis represent the forms most commonly seen in terms of occupation.

Abbreviations

| Abbreviation | Description |
|--------------|-------------|
| DD           | Differential diagnosis |
| LST          | Lymphocyte stimulation test |
| LTT          | Lymphocyte transformation test |
| MELISA       | Memory lymphocyte immunostimulation assay |
| PPD          | Paraphenylenediamine |
| PUVA         | Psoralen plus UV-A |
| ROAT         | Repeated open application test |
| UV           | Ultraviolet |
Irritant contact dermatitis is often the precursor of further contact sensitization [9]. Allergic and irritant contact dermatitis are common diseases seen in many countries where they are by no means only work-related and where they generate considerable public-health and socio-economic costs [10, 11, 12].

Prevalence of contact dermatitis

The proportion of the German population estimated to be affected by some form of contact dermatitis is estimated at 15%–20% [12]. It is not unusual for children to be affected and some studies show that the incidence is rising among the pediatric population [13, 14, 15]. Contact eczema is also frequently seen in older adults as a result of age-related differences in exposure, changes in epidermal barrier function, and alterations in immune reactivity [16, 17]. According to a German health survey carried out in 2000 (Gesundheitssurvey 2000 [18]), the lifetime prevalence of allergic contact dermatitis is around 15% and the annual prevalence approximately 7%.

Danish studies in the 1990s reported a lifetime prevalence of hand dermatitis of 17%, and already in adolescents aged between 12 and 16 years the prevalence was 7% [19]. In Gothenburg, Sweden, the point prevalence of hand dermatitis among individuals aged between 20 and 65 years was 5.4% and the 1-year prevalence 10.6% [20]. On the basis of a review of original articles from the last 30 years, a point prevalence of hand dermatitis of 4% was determined [21], whilst a 1-year prevalence of 2% was given for acute contact allergic dermatitis of the hand. According to this review, the 1-year prevalence of hand dermatitis in general was approximately 10% [21]. In a patient collective of the Information Network of Dermatological Clinics (IVDK), hand dermatitis accounted on average for approximately a third of all forms of contact dermatitis; assuming an equivalent proportion in Sweden would yield a prevalence of allergic contact dermatitis of 6% [19]. Thus, the 1-year prevalence of 7% determined by the German health survey appears to demonstrate relatively stable development over the decades [18]. Allergic contact dermatitis is undoubtedly a widespread disease with an incidence similar to that of diabetes.

Incidence of contact dermatitis

In the Netherlands, an incidence of 7.9 per 1000 person-years was observed for non-etiologically defined contact dermatitis [22]. Incidences determined for selected occupations are significantly lower.
higher [23, 24]. An incidence of allergic contact dermatitis of 28 per 1000 per year was calculated in a collective made up of students at a university dermatological out-patient department in the US [19]. Using urban sample populations, British colleagues calculated an incidence of 0.6 per 1000 per year. If this rate were to be corrected by a factor that takes the consultation rate into consideration, the incidence would stand at 1.6 per 1000 per year.

Using a calculation model for a “moderate” scenario (assumptions lying somewhere between the two possible extremes), the incidence of allergic contact dermatitis was estimated at 3 per 1000 per year [25].

Maxim: As a public health problem, allergic contact dermatitis affects all age groups with a high prevalence and incidence.

Clinical picture of contact dermatitis
Clinical presentations of contact dermatitis
Tab. 1 shows the “classic” clinical forms of contact dermatitis.

Clinical symptoms depend primarily on whether the dermatitis is acute or chronic, as well as on the toxin involved, type of contact, pathomechanism, and localization, among other factors (Tab. 2) [26]. Although all types of dermatitis generally share common features, the classic eczematous stages in contact dermatitis (allergic and irritant) are most readily identifiable. Therefore, this particular variant of dermatitis is considered the classic example [26, 27].

Acute-stage eczematous reaction
Acute contact dermatitis is characterized by a largely uniform metachronous sequence of pathological symptoms over the entire lesion.

- Mild form: erythema at the site of exposure to the toxin, contact traces, and itching are possible.
- Severe form: ranging from vesicular papules (histologically: spongiotic blisters) to blisters, usually causing strong itching. A feeling of tightness of the skin and even pain may occur. Blister rupture is followed by weeping, scab formation, and later by scaliness, generally culminating in restitutio ad integrum. Spreading reactions are possible in the case of an allergic trigger.

Acute irritant contact dermatitis is characterized by: rapid onset (within hours) following generally easy-to-identify exposure, rapid clinical course, and usually also rapid resolution; its monomorphic and often highly intensive clinical symptoms (including possible skin necrosis); subjective symptoms perceived more as burning pain than itching; and clearly demarcated borders around the area of contact and the absence of spreading.

Chronic dermatitis
Chronicity occurs when the skin continues to be exposed to the toxin, thereby preventing spontaneous healing of the dermatitis, or when the dermatitis persists even in the absence of the toxin.

From a morphological perspective, there are eczematous plaques with focal emphasis in more exudative or scalier areas. The initially relatively sharp demarcation becomes increasingly indistinct. The skin has a thickened appearance due to the infiltration of inflammatory cells and skin folds become accentuated (lichenification). The clinical picture is increasingly dominated by hyperkeratoses, rhagades, and lichenification.

The onset of chronic degenerative contact dermatitis is first seen after exposure lasting in some cases for up to years. The initial symptom is generally uncomfortable dryness of the skin, followed by erythema and flaking. Thereafter, it is characterized by a dry, hyperkeratotic-scaly, fissured/rhagade-like lesion of a less exudative nature. It follows a slow clinical course and heals only in a delayed manner, is largely – but not exclusively – restricted to the area of contact, and does not show a tendency to spread.

### Table 2

**Exogenous and endogenous factors affecting the inflammatory reaction and thus the clinical characteristics of dermatitis (adapted from [26])**

| Exogenous factors | Endogenous factors |
|-------------------|-------------------|
| Type of toxin (allergen, irritant, chemical structure, pH) | Individual sensitivity to the irritant |
| Quantity of the penetrating substance (solubility, vehicle, concentration, type and duration of application) | Specific immunological sensitization |
| Body area | Primary hyperirritable (sensitive) skin |
| Body temperature | Predisposition to atopic dermatitis |
| Mechanical factors (pressure, friction, abrasion) | Incapacity to “harden” |
| Chemical and physical factors (water, solvent, cold, UV radiation, etc.) | Secondary hyperirritability (status eczematicus) |
| Climatic conditions (temperature, humidity, wind) | Ethnic factors |
| Partner contact | Age |
| | Sensitivity to UV radiation |
| | Genetic disposition |
| | Polysensitization |
| | Pre-existing dermatoses (e.g., lower leg dermatitis) |
The development of dermatitis varies not only according to its course over time, but also according to body region and is co-determined by the type and aggressivity of the triggering agent and other parameters (Tab. 2). Relevant genetic factors are currently the subject of numerous studies [28, 29, 30, 31, 32, 33, 34, 35].

The varying localizations of dermatitis are not only suggestive of possible triggers, but sometimes also of the pathogenetic mechanisms involved. Typical sites of predilection for the initial symptoms of allergic contact dermatitis include the back of the hand and the lateral sides of the finger. Dermatitis triggered by ultraviolet (UV) light is, at least initially, restricted to areas exposed to light and spares facial areas shaded by the chin, ears, etc., as well as areas of the body covered by hair or clothing. Dermatitis on exposed areas of the body can also be triggered by airborne allergens, such as plant allergens or volatile substances in the workplace (e.g., epoxide resins) [36] (airborne contact dermatitis).

The various localizations of dermatitis can produce specific morphology. For example, angioedema-like swelling of the eyelids is often the only manifestation seen in the facial area, whereas dermatitis on the lower legs can appear “striped” following contact with plants, and textile dermatitis is typically worse in areas coming into intense contact with fabric (often intertriginous areas, e.g., armpits, groin). Due to the thick stratum corneum on the palms of the hands and soles of the feet, microscopic blisters can develop into large eruptions by means of confluence (Cheiropodopompholyx). Occasionally, once healed, post-inflammatory hypo- or hypopigmentation may be seen. Scarring or granulomas develop only in very rare cases.

In contrast to irritant contact dermatitis, allergic contact reactions may exhibit spreading phenomena. Although the precise pathomechanism of these spreading reactions is unknown, intensive allergen contact and hematogenous distribution of the allergen or generalized activation of immunological effector cells are suspected pathways [37], among others.

Individual predisposing factors, particularly in chronic-degenerative dermatitis, are of considerable relevance, such as an underlying predisposition to atopic dermatitis or – usually age- or care-related – exsiccation of the skin. This frequently results in a combined pathogenesis of dermatitis. “Grafted allergies”, i.e., the development of a contact allergy in the setting of an existing chronic-degenerative dermatitis, are not uncommon. Mixed clinical presentations comprising allergic and chronic-degenerative dermatitis are often challenging to classify from a clinical and differential diagnostic point of view. Secondary bacterial colonization (frequently with staphylococci, particularly in weeping dermatitis), dermatophytes (notably on hands and feet), or candida infections (body folds, particularly in infants and diabetics), and less commonly viruses make diagnosis difficult and complicate therapy. Pustules in the setting of dermatitis can lead not only to secondary infections, but also to weeping dermatitis in cases where inadequate occlusive ointment treatment is administered.

In brief: Dermatitis seen as the “final common pathway” of widely varying entities is affected by multiple variables. Diagnosis requires a differentiated approach, usually involving patch testing.
Non-eczematous clinical presentations of contact allergic reactions
These may be triggered by epicutaneous, cutaneous, and systemic allergen exposure [27, 37, 38, 39, , 40, 41]. Unusual contact allergens may be relevant [42]. The most important non-eczematous reaction patterns are shown in Tab. 3.

Note: Skin reactions to external contact agents can sometimes produce a clinical picture that is not suggestive of dermatitis at first glance.

Diagnosis
Patient history and the clinical picture are crucial to the diagnostic process. The most important differential diagnoses are summarized in Tab. 4.

Histological analysis of a skin biopsy is indicated in all cases showing atypical symptoms or clinical course.

Patient history includes questions relating to the development of the dermatitis and allergen exposure, as well as an assessment of causality. Once patch test results are available, questions relating to allergen exposure often need to be repeated in a second patient history. Due to the complexity of possible types of exposure, supplementary questionnaires to aid patient history taking have been developed for a number of occupations [43, 44, 45, 46, 47, 48, 49, 50].

The suspicion that dermatitis has been caused by exposure to an exogenous trigger is formed on the basis of allergen and/or toxin exposure and the clinical picture. In irritant contact dermatitis, the trigger is usually exposure of the skin to an irritant, such as frequent or prolonged contact with water, solvents and cleaning agents, dust, etc., that predominantly cause irritant reactions. The diagnosis of allergic contact dermatitis is made by detecting contact sensitization to causative allergens by means of patch testing. A detailed description of how to perform patch tests and evaluate their relevance is given in the relevant DDG guidelines [51]. It is essential to use approved test substances (e.g., as in the series of tests recommended by the DKG), apply the patches in a methodically correct manner, and take a reading of reactions by the third day at the latest.

If no plausible result is achieved using a conventional patch test despite suspected contact allergy, modified patch testing methods are considered [52, 53, 54, 55, 56, 57, 58] (Tab. 5).

The methods described in Tab. 5 require particular experience and should therefore only be carried out by specialists.

| Modifications and additions to patch testing | Table 5 |
|---------------------------------------------|---------|
| For the "strip" patch test, the horny layer is reduced prior to allergen application |        |
| For the repeated open application test (ROAT), a suspected allergen is repeatedly applied openly over several days |        |
| Although the atopy patch test enables atopic individuals to be investigated for airborne and food allergens following late phase reactions [52], the test has not yet been sufficiently validated [3][59]. For certain substances (e.g., drug preparations approved for intravenous use) intracutaneous testing with delayed readings can be helpful; however, cross-center validation is still lacking for this method |        |
| Additional scratch testing can be helpful if adequate transdermal administration of the test substance is not possible with patch testing. Delayed readings over several days are necessary |        |
| Prick testing (or intracutaneous testing) can also be helpful in the case of suspected protein contact allergy; again, delayed readings are required |        |

In brief: The diagnosis of contact dermatitis is based on patient history, clinical examination, and skin testing. Additional investigations may be necessary.

The lymphocyte-transformation or -stimulation tests (LTT or LST) and their modifications (e.g., memory lymphocyte immunostimulation assay, MELISA) should be used for scientific or highly specialized clinical investigations. Performing these tests is technically challenging and the methods are poorly standardized; thus, LTTs should remain the reserve of specialist laboratories that have particular experience with these test methods and the interpretation of their results. In the absence of a critical evaluation of LTT results in comparison with patch test results, possibly also a repeated open application test (ROAT) or exposed control person, their relevance is questionable and should not form the basis for prophylactic or therapeutic measures [60, 61, 62]. In exceptional cases involving very strong patch test reactions to para-phenylenediamine (PPD), LTTs can be helpful in preventing reactions due to cross-sensitization in further testing [61, 63]. Other in vitro methods for the diagnosis of contact allergies are not validated.

The guidelines of the German Association of Scientific Medical Societies (AWMF) (register number: 061/017, Renz et al.) state in this regard: “In high concentrations, some contact allergens can also function as mitogens (i.e., obligatory stimuli), making individual titration necessary. Whether the of-
ten poor specificity of LST for the analysis of metal compounds can be attributed to non-optimized conditions is unclear. Especially good correspondence between LST and patch testing is achieved for nickel sulfate in particular. However, from a dermatological point of view, there is no clinical indication to favor the complex in vitro test that is not validated for most allergens over the patch test, thereby leaving the real value of the LST in relation to contact allergens squarely in the domain of scientific investigations (and further development of the test system). Indiscriminate use of LST (or modifications thereof, such as MELISA) in the diagnosis of mercury allergies should be rejected.”

Note: LTT (LST) is indicated in scientific, however generally not in clinical investigations of contact allergies.

There is currently no useful diagnostic test for the direct identification of irritant contact dermatitis [64]. Alkaline resistance testing, the Nitrazine yellow swab test, or measuring transepidermal water loss do not represent reliable diagnostic aids. Thus, the diagnosis of irritant contact dermatitis is made on the basis of patient history and clinical picture – once possible causal contact sensitization has been excluded – and can be indirectly confirmed by subsequent resolution following cessation of toxin exposure.

Treatment
Patient information
The successful treatment of contact dermatitis requires patient cooperation. The information provided to the patient and their mastery of the treatment, as well as care and protection measures, can contribute significantly both in terms of treatment and prophylaxis, particularly where occupation-related dermatitis triggers are relevant [65, 66, 67].

Avoiding the noxa
Contact dermatitis is triggered by exogenous toxins in the vast majority of cases. The most important therapeutic approach, therefore, is to cease causal exposure – no form of symptomatic treatment can substitute for this approach. Attempts to induce tolerance to contact allergens by means of immunotherapy have been hitherto unsuccessful [7, 68].

Where it is not possible to fully eliminate or avoid a triggering contact substance (allergen or irritant) in the individual’s immediate environment, protective measures to prevent renewed skin contact are indicated. These include: personal protective clothing (often primarily protective gloves in the case of hazardous activities), work-related precautionary measures (modifying work processes, avoiding wet/humid work conditions, using extraction systems), and consistent stage-related treatment [69, 70]. These measures need to be tailored to the individual situation (toxic substance, type of exposure). Prolonged use of gloves should be avoided due to their occlusive effect, although these effects are apparently milder than originally assumed [71]. Adjuvant use of suitable skin barrier creams can be helpful [72, 73]. The selection of gloves and barrier creams should be made on the basis of their efficacy against the relevant toxins [74].

Dietary measures can be helpful in cases where a systemic hematogenous triggering of contact dermatitis in the setting of high-grade sensitization to an orally-ingested contact allergen is diagnosed (as evidenced by patient history, patch testing, exclusion diet, and diagnostic provocation). Under this premise, a low-nickel diet may improve symptoms in individuals allergic to nickel [75, 76, 77, 78], whilst chelating agents have also been described as helpful [79, 80].

Maxim: Avoiding the diagnostically determined noxa(e) is crucial.

Symptomatic treatment of contact dermatitis
Topical treatment is generally sufficient. As with other inflammatory dermatoses, the base in which the active substance is applied must be tailored to the severity of the dermatitis. Acute dermatitis is generally moist and needs to be treated with a hydrophilic preparation (gel, lotion, cream), whereas chronic disease is more likely to require a water-in-oil-based preparation (ointment). Needless to say, the base should not contain any allergens that may be relevant to the patient.

Corticosteroids
The efficacy of topical treatment with class-II or -III corticosteroids in acute allergic contact dermatitis is undisputed [81]; stronger preparations are required only in exceptional cases. However, weaker preparations at least do not always produce any detectable effect in irritant contact dermatitis [53]. The selection of a suitable corticosteroid with the appropriate efficacy should be made on the basis of the localization of skin lesions, as well as the severity and acuteness of the dermatitis, whilst bearing the therapeutic index in mind [82, 83]. Where long-term therapy is indicated, preparations bearing low risk of atrophy (e.g. mometasone furoate, methylprednisolone aceponate, hydrocortisone butyrate) are preferred [84, 85].
The general principles governing the use of corticosteroids apply equally to their use in the treatment of contact dermatitis. The known side effects of topical treatment must be borne in mind when deciding upon the type and duration of treatment.

Hence, topical corticosteroids represent the medication of first choice for the symptomatic treatment of contact dermatitis.

Calcineurin antagonists
In Germany, Austria, and Switzerland, calcineurin antagonists are only approved for the treatment of atopic dermatitis. They are less effective than strong corticosteroids in manifest contact dermatitis [87, 88, 89, 90, 91, 92, 96]. However, if long-term use is indicated, topical calcineurin antagonists may be beneficial in contact dermatitis compared to corticosteroids, particularly in sensitive areas of the skin (e.g., face, intertriginous areas), since they carry no atrophy risk [93]. With regard to safety, the reader is referred to the AWMF guidelines of the DDG on topical calcineurin antagonists and neurodermatitis [85, 94].

Ultraviolet therapy
Short-wave ultraviolet light (UVB) and PUVA (psoralen plus UV-A) are effective in chronic dermatitis, most notably in hand dermatitis [70, 95, 96, 97, 98]. In some forms of hand dermatitis, topical application of psoralens is advisable in the context of PUVA therapy in order to intensify the therapeutic effect. It appears possible to achieve a certain degree of “protective hardening” using UVB [101]. Positive data are also available on the use of UVA1 and narrow-band UVB, particularly in hand dermatitis [102, 103, 104].

Other external agents
Due to its antiphlogistic and antiproliferative effects, the use of coal tar as a follow-up treatment is still reasonable today in cases where other external agents are ineffective or declined by the patient. There is no evidence to support the fear that local treatment with coal tar is carcinogenic [105, 106, 107, 108, 109]. However, the known side effects of coal tar treatment (skin irritation and discoloration, acnegenic effect, photosensitization) must be borne in mind. Antiseptic agents such as triclosan, polyhexanide, octenidine, etc., are helpful in the elimination of germs in pathogenic microbial colonization. Iontophoresis can be beneficial in dyshidrotic dermatitis [110]. Soft X-ray therapy and Grenz ray therapy have proven to be helpful in the treatment of dermatitis [111, 112, 113, 114]. However, due to the harmful cumulative effects of X-rays to the skin, these methods are in principal contraindicated today and only justified in exceptional cases. The efficacy of topical non-steroidal antiphlogistic agents in contact dermatitis has not been sufficiently proven; in addition, there is a relevant risk of contact sensitization to these substances when used topically in dermatitis [115, 116]. Although Bufexamac has had its approval withdrawn by the European Medicines Agency due to its sensitization potential, it is still available in Switzerland and outside Europe. Moreover, many other substances for which no published data on efficacy are available are nevertheless used and recommended for the treatment of dermatitis. The same is true for antihistamines.

Systemic treatment
Systemic treatment may become necessary in cases where local treatment is insufficiently effective. It is essential to take the specific side-effects profile of the agents used into consideration.

Short-term systemic corticosteroid therapy (from 3 days up to 2 weeks) may be indicated, particularly for extensive contact dermatitis in acute, severe, and/or therapy-refractory cases, frequently in the case of systemic contact dermatitis (hematogenous contact dermatitis). The usual rules on systemic administration of corticosteroids apply here. Systemic administration of alitretinoin may be helpful in chronic hand eczema [117, 118, 119, 120]. In this regard, the reader is referred to the guidelines on hand dermatitis [1]. Insufficient data is available to date on the long-term effects [119]. Cyclosporine is currently the drug of first choice in the treatment of severe, therapy-resistant atopic dermatitis in adults, an indication for which it is approved. Long-term oral administration of cyclosporine A can be helpful in patients with therapy-resistant hand dermatitis [121, 122]. Other immunomodulators, such as azathioprine, mycophenolate mofetil, or methotrexate are also used for atopic dermatitis off-label (but only if cyclosporine is ineffective or contraindicated), and can also be considered for contact dermatitis [94, 123, 124].

Basic therapy and skin protection
Follow-up treatment with basic moisturizing agents to promote skin barrier regeneration and protect against recurrence, combined with the use of skin protection creams, is beneficial when individually tailored to skin status and skin exposure [125, 126, 127]. On the other hand, preparations containing unsuitable levels of water and fat or allergenic components may delay the resolution of dermatitis or even intensify the effect of substances harmful to the skin [127]. Although skin protection training is beneficial in the case of hazardous occupational ex-
posure [128], the effectiveness of skin protection creams alone under working conditions has not be unequivocally proven [129]. Complete restoration of barrier function is not expected until several weeks after the clinical resolution of contact dermatitis. However, the beneficial effect of moisturizers is measurable [130].

**Evidence of therapeutic efficacy**

Only a small number of prospective, randomized, double-blind, controlled studies meeting current criteria have proven the efficacy of the contact dermatitis treatments mentioned here in sufficiently large patient populations.

Relevant data supporting efficacy is only available for the use of topical corticosteroids and systemic administration of altretinoin in hand dermatitis [84, 131, 118]. However, this does not mean by implications and accident insurance institutions, speaker’s consultant/expert for employer’s liability insurance association) [132]. However, if the reasonable suspicion of an occupational disease has already been confirmed, i.e., ceasing the activity appears the only option once all avenues of prevention have been explored, it is legally required of the treating physician to report an occupational disease (in Germany, using form F6000) [133].

**Reporting dermatitis**

It is generally necessary to establish whether a case of contact dermatitis has been triggered by occupational exposure. Where work-related causality is possible, a dermatological report is drawn up – with the patient’s consent – to the relevant statutory accident insurance (e.g., employer’s liability insurance association) [132]. However, if the reasonable suspicion of an occupational disease has already been confirmed, i.e., ceasing the activity appears the only option once all avenues of prevention have been explored, it is legally required of the treating physician to report an occupational disease (in Germany, using form F6000) [133].

**Note:** Individually tailored systemic therapy should be considered when topical therapy is either ineffective or unfeasible.

**Prof. Dr. Jochen Brasch**

Klinik für Dermatologie, Venerologie und Allergologie Universitätsspital Schleswig-Holstein, Campus Kiel Schittenhelmstraße 7
24105 Kiel
E-Mail: jbrasch@dermatology.uni-kiel.de

**Conflicts of interest**

The corresponding author states the following: D. Becker: consultant/expert for employer’s liability insurance associations and accident insurance institutions, speaker’s fees for Almirall und Basilea; T. Biedermann: research funding from Novartis; T. Diepgen: consultant/expert for, among others, Spirig Pharma GmbH, Basilea Pharmaceutica Int., Procter & Gamble, Evonik Industries AG, Firmenich SA, Novartis, speaker’s/training fees for, among others, Actelion Pharmaceuticals, Almirall, Spirig Pharma GmbH, Astellas Pharma GmbH, Basilea Pharmaceutica Ltd., Leo Pharma, funding for research projects, etc., from Intendiens Pharmaceuticals, Basilea Pharmaceutica Int., Firmenich SA; P. Elsner: speaker’s fees from Astellas, Basilea, Galderma, Leo, Novartis, Roche, Spirig; K. Jung: consultant/expert for Meda, speaker’s fees from ALK-Abelló, Meda, Novartis; S. M. John: speaker’s fees from Smartpractice, Spirig; B. Kränke: speaker’s fees from; H. Merk: consultant/expert for ALK, Novartis, AOK, Bayer, speaker’s fees from, among others, ALK, Novartis, AOK, Stalergene, funding for research projects from, among others, Therma Fisher, Bayer; B. Przybilla: consultant/expert for Janssen, speaker’s fees from ALK-Abelló; A. Schnuch: consultant/expert for bristol; T. Werfel: consultant/expert for Lüllau GmbH, Novartis, speaker’s fees from Meda, Biogen, Janssen, Novartis, Astellas, funding for research projects from Biogen, Novartis, Astellas; W. Aberer, A. Bircher, J. Brasch, T. Fuchs, and A. Trautmann state that they have no conflicts of interest.

**Cite this as**

Brasch J, Becker D, Aberer W, Bircher A, Kränke B, Jung K, Przybilla B, Biedermann T, Werfel T, John SM, Elsner P, Diepgen T, Trautmann A, Merk HF, Fuchs T, Schnuch A. Guideline contact dermatitis. S1-Guideline of the German Contact Allergy Group (DXG) of the German Dermatology Society (DDG), the Information Network of Dermatological Clinics (IVDK), the German Society for Allergology and Clinical Immunology (DGAKI), the Working Group for Occupational and Environmental Dermatology (ABD) of the DDG, the Medical Association of German Dermatologists (AeDA), the Professional Association of German Dermatologists (BVDD) and the DDG. Allergo J Int 2014; 23: 126–38

DOI 10.1007/s40629-014-0013-5

**References**

1. Diepgen TL, Elsner P, Schiemann S, Fartasch M, Köllner A, Skudlik C et al; Deutsche Dermatologische Gesellschaft. Guideline on the management of hand eczema (ICD-10 Code: L20. L23. L24. L25. L30. J Dtsch Dermatol Ges 2009; 7 Suppl 3: S1–16

2. Brasch J, Becker D, Aberer W, Bircher A, Kränke B, Denzer-Fürst S et al. Kontaktallergie. Hautarzt 2011; 62: S1–16

3. Schnuch A, Geier J, Lessmann H, Arnold R, Uter W. Surveillance of contact allergies: methods and results of the Information Network of Departments of Dermatology (IVDK). Allergy 2012; 67: 847–57

4. Uter W, Aberer W, Armario-Hita JC, Fernandez-Vozmediano JM, Ayala F, Balato A et al. Current patch test results with the European baseline series and extensions to it from the ‘European Surveillance System on Contact Allergy’ network, 2007–2008. Contact Dermatitis 2012; 67: 9–19

5. Geier J, Uter W, Lessmann H, Schnuch A. Aktuelle Kontaktallergene. Hautarzt 2011; 62: 751–6

6. Schnuch A, Geier J, Lessmann H, Arnold R, Uter W. Surveillance of contact allergies: methods and results of the Information Network of Departments of Dermatology (IVDK). Allergy 2012; 67: 847–57

7. Uter W, Aberer W, Armario-Hita JC, Fernandez-Vozmediano JM, Ayala F, Balato A et al. Current patch test results with the European baseline series and extensions to it from the ‘European Surveillance System on Contact Allergy’ network, 2007–2008. Contact Dermatitis 2012; 67: 9–19

8. Smedley J; OHCEU Dermatitis Group; BOHRF Dermatitis Groups. Concise guidance: diagnosis, management and prevention of occupational contact dermatitis. Clin Med 2010; 10: 487–90

9. Smedley J; OHCEU Dermatitis Group; BOHRF Dermatitis Groups. Concise guidance: diagnosis, management and prevention of occupational contact dermatitis. Clin Med 2010; 10: 487–90
48. Uter W, Wulfhorst B, Pitz B, Raguz J. Anamnese-Auxilium für das Friseurgewerbe – dermatologisches Risikoprofil. Dermatol Beruf Umwelt 1997; 45: 165–9
49. Uter W. Epidemiologie und Prävention von Handkernwunden in Feuchterwerben am Beispiel des Friseurhandwerks. Osnabrück: Universitätsverlag Rasch, 1999
50. Weißbecher R, Straube M, Szliska C, Schwanitz-H. Anamneseausschluss und gewerbemedizinologische Beurteilung bei medizinischen Bademeistern, Masserinnen und Physiotherapeuten. Hautartz 1998; 49: 912–9
51. Schnuch A, Aberer W, Agathos M, Becker D, Brusch J, Elsner P et al. Durchführung des Epikutantests mit Kon- taktkeratogenen. J Dtsch Dermatol Ges 2008; 9: 770–5
52. Darsow U, Ring J. Atopie-Patchtest mit Aeroallergenen und Nahrungsmitteln. Hautartz 2005; 56: 1133–40
53. Levin C, Zhai H, Bashir S, Chew AL, Anigbogu A, Stern R et al. Efficacy of corticosteroids in acute experimental irritant contact dermatitis. Skin Res Technol 2001; 7: 214–8
54. Fischer LA, Voelund A, Andersen KE, Menné T, Johansen JD. The dose-response relationship between the patch test fluid ROAT and the potential use for regulatory pur-
poses. Contact Dermatitis 2009; 61: 201–18
55. Goossens A. (Alternatives to patch tests). Ann Dermatol Venereol 2009; 136: 623–5
56. Nino M, Patruno C, Zangaria O, Balato N. Allergic contact dermatitis from heparin-containing gel: use of scratch patch test for diagnosis. Dermatitis 2009; 20: 171–2
57. Dickel H, Altmeyer PE, Brusch J. „New“ techniques for more sensitive patch testing? J Dtsch Dermatol Ges 2011; 9: 889–96
58. Dickel H, KrefT B, Kuss O, Worm M, Soost S, Brusch J et al. Increased sensitivity of patch testing by standardized tape stripping beforehand: a multicentre diagnostic accuracy study. Contact Dermatitis 2010; 62: 294–302
59. Lipopenzic J, Wolf RJ. The diagnostic value of atopic patch testing and prick testing in atopic dermatitis: facts and controversies. Clin Dermatology 2010; 28: 38–44
60. Breherl R, Merk H. In vitro testing for allergic contact dermatitis. Hautartz 2005; 56: 1141–3
61. Skazik C, Grannemborg S, Willers L, Merk HF, Coenraads PJ, Breuer S et al. Reactivity of in vitro activated human T lymphocytes to p-phenylenediamine and related sub-
stances. Contact Dermatitis 2008; 59: 203–11
62. Skazik C., Merk HF, Baroni JM. Diagnose der Kontaktaller-
gie: Warum In-Vitro-Testsysteme? Hautartz 2008; 59:
339–42
63. Knellning M, Caroli U, Grimmel C, Fischer J, Eichner M, Wieder T et al. Para-phenylenediamine-specific lym-
phocyte activation test: a sensitive in vitro assay to de-
tect para-phenylenediamine sensitization in patients with severe allergic reactions. Exp Dermatol 2010; 19: 435–41
64. Slodownik D, Lee A, Nixon R. Irritant contact dermatitis: a review. Australas J Dermatol 2008; 49: 1–9
65. Andersen F, Andersen KE. Management of irritant contact dermatitis: continuously a problem for patients and der-
matologists. Ital Dermatol Venereol 2008; 143: 207–12
66. Nicholson PJ, Llewellyn D, English JS. Guidelines Develop-
ment Group. Evidence-based guidelines for the pre-
vention, identification and management of occupa-
tional contact dermatitis and urticaria. Contact Dermatitis 2010; 63: 177–86
67. Seyfarth F, Schlimemann S, Antonov D, Elsner P. Teaching interventions in contact dermatitis. Dermatitis 2011; 22: 8–15
68. Spiewak R. Immunotherapy of allergic contact dermatis-
tis. Immunotherapy 2011; 3: 979–96
69. Wassilew SW. Hautschutz am Arbeitsplatz. In: Plewig G, Przybilla B, Hirsch. Fortschritte der praktischen Dermatol-
ogie und Venerologie. Berlin – Heidelberg: Springer, 1997. S. 182–5
70. Warshaw E, Lee G, Storrs FJ. Hand dermatitis: a review of clinical features, therapeutic options, and long-
term outcomes. Am J Contact Dermatitis 2003; 14: 119–37
71. Wetzyk U, Bock M, Wulfhorst B, John SM. Short- and long-term effects of single and repetitive glove occlusion on the epithelial barrier. Arch Dermatol Res 2009; 301: 595–602
72. Saary J, Krennhi R, Palda V, DeKoven J, Pratt M, Skot-
nicki-Grant S et al. A systematic review of contact der-
matitis treatment and prevention. J Am Acad Dermatol 2005; 53: 845
73. Zhai H, Maibaum HI. Protection from irritants. Curr Probl Dermatol 2007; 34: 47–57
74. Wulfhorst B, Bock M, Skudlik C, Wigger-Alberti W, John SM. Prevention of hand eczema – gloves, barrier creams and workers’ education. In: Duus Johansen J, Frosch PJ, Lepoittevin JP, eds. Contact Dermatitis. Berlin – Heidel-
berg: Springer, 5th ed. 2011. S. 985–1028
75. Bresser H. Orale Nickelprovokation und nickelarme Diät. Indikationen und praktische Durchführung. Hautartz 1992; 43: 610–5
76. Behr-Völter C, Hamm M, Vieluf D, Ring J. Diatemp-
fehlungen bei Nickelunverträglichkeit. Allergo J 1997; 6: 197–203
77. Antico A, Soana R. Chronic allergic-like dermatopathies in nickel-sensitive patients. Results of dietary restric-
tions and challenge with nickel salts. Allergy Asthma Proc 1999; 20: 235–42
78. Erdmann SM, Wefel T. Hematogenous contact eczema induced by foods. Hautartz 2006; 57: 116–20
79. Kaaber K, Menné T, Veien N, Hougaard P. Treatment of nickel dermatitis with Antabus; a double blind study. Contact Dermatitis 1985; 9: 297–9
80. Fowler JF. Disulfiram is effective for nickel allergic hand eczema. Am J Contact Dermatitis 1992; 3: 175–8
81. Levin C, Maibaum HI. An overview of the efficacy of topi-
cal corticosteroids in experimental human nickel con-
tact dermatitis. Contact Dermatitis 2000; 43: 317–21
82. Niedner R. Grundlagen einer rationalen Therapie mit e-
ternen Glukokortikoiden. Hautartz 1991; 42: 337–46
83. Luger TA, Loske KD, Elsner P, Kapp A, Kerscher M, Kort-
ing HC et al. Topische Dermatotherapie mit Glukokor-
tikoiden – therapeutischer Index. JDDG 2004; 2: 629–34
84. Veien NK, Olhoin Larsen P, Iversrup-Pedersen K, Schou G. Long-term, intermittent treatment of chronic hand eczema with betametasone furoate. Br J Dermatol 1999; 140: 882–6
85. Luger TA, Gollnick H. Stellungnahme der Deutschen Dermatologischen Gesellschaft (DDG) zur Entscheidung der amerikanischen Arzneimittelbehörde über die Ver-
wendung von Pimecoliminikus-Creme und Tacrolimus-Salbe zur Behandlung der atopischen Dermatitis (Neuro-
dermatitis). JDDG 2005; 3: 415–6
86. Wollina U. The role of topical calcineurin inhibitors for skin diseases other than atopic dermatitis. Am J Clin Dermatol 2007; 8: 157–73
87. Meingassner JG, Fahringerhuber H, Buvandi A. Pimecolimus inhibits the elicitation phase but does not suppress the sensitization phase in murine contact hypersensitivity, in contrast to tacrolimus and cyclosporine A. J Invest Dermatol 2003; 121: 77–80
88. Saripalli YV, Gadzia JE, Belsito DV. Tacrolimus ointment 0.1 % in the treatment of nickel-induced allergic contact dermatis. J Am Acad Dermatol 2003; 49: 477–82
89. Amrol D, Keitel D, Hagaman D, Murray J. Topical pimecolimus in the treatment of human allergic con-
tact dermatitis. Ann Allergy Asthma Immunol 2003; 91: 563–6
90. Alomar A, Puig L, Gallardo CM, Valenzuela N. Topical ta-
crolimus 0.1 % ointment (protopic) reverses nickel con-
tact dermatitis elicited by allergen challenge to a similar
degree to mometasone furoate 0.1% with greater suppression of late erythema. Contact Dermatitis 2003; 49: 163–8.

91. Quelle-Roussel C, Graeber M, Thurston M, Lachapelle JM, Decroix J, Cuyper C de et al. SDZ ASM 981 is the first non-stoicid that suppresses established nickel contact dermatitis elicited by allergen challenge. Contact Dermatitis 2000; 42: 349–70.

92. Krejci-Manwaring J, McCarthy MA, Camacho F, Manuel J, Hartje J, Fleischer A et al. Topical tacrolimus 0.1% improves symptoms of hand dermatitis in patients treated with a prednisone taper. J Drugs Dermatol 2008; 7: 643–6.

93. Aschoff R, Schmitt J, Knuschke P, Koch E, Brautigam M, Meurer M. Evaluation of the atrophogenic potential of hydrocortisone 1% cream and pimecrolimus 1% cream in uninvolved forehead skin of patients with atopic dermatitis using optical coherence tomography. Exp Dermatol 2011; 20: 832–6.

94. Werfel T, Abeler W, Augustin M, Biedermann T, Fölster-Holst R, Friedrichs F et al. Atopic dermatitis: 52 guidelines. J Dtsch Dermatol Ges 2009; 7 Suppl 1: 51–46.

95. Mork NJ, Austad J. Short-wave ultraviolet light (UVB) treatment of allergic contact dermatitis of the hands. Acta Derm Venereol 1983; 63: 87–9.

96. Sjövall P, Christensen OB. Local and systemic effect of Mork NJ, Austad J. Short-wave ultraviolet light (UVB) treatment of allergic contact dermatitis of the hands. Acta Derm Venereol 1983; 63: 87–9.

97. Sjövall P, Christensen OB. Treatment of chronic hand eczema with UV-B Handtux in the clinic and at home. Contact Dermatitis 1994; 31: 5–8.

98. Stege H. Ultravioletterapie des chronischen Handekzems. Hautarzt 2008; 59: 696–702.

99. Grittiyaringsan P, Sukhum A, Tresukosol P, Kullavanijaya P. Topical PUVA therapy for chronic hand eczema. J Dermatol 1998; 25: 299–301.

100. Izenava S, Kittler H, Thallinger C, Honigsmann H, Ianew A. Oral vs. bath PUVA using 8-Methoxypsoralen for chronic palmoplantar eczema. Photodermatol Photoinmunol Photomed 2009; 25: 101–5.

101. Bauer A, Kelterer D, Bartsch R, Schlegel A, Pearson J, Stadler M et al. Prevention of hand dermatitis in bakers’ apprentices: different efficacy of skin protection measures and UVB hardening. Int Arch Occup Environ Health 2002; 75: 491–9.

102. Schmidt T, Abeck D, Bock K, Mempel M, Ring J. UVA1 irradiation is effective in treatment of chronic vesicular dyshidrotic hand eczema. Acta Derm Venereol 1997; 78: 318–9.

103. Petering H, Breuer C, Herbst R, Kapp A, Werfel T. Comparison of localized high-dose UV1 irradiation versus topical cream psoralen-UVA for treatment of chronic vesicular dyshidrotic eczema. J Am Acad Dermatol 2004; 50: 68–72.

104. Sezer E, Ertikan I. Local narrowband UVB phototherapy vs. local PUVA in the treatment of chronic hand eczema. Photodermatol Photoinmunol Photomed 2009; 25: 101–5.

105. Cholchka W, Leuschner J, Leuschner F. The tolerability of pale sulfonated shale oil following local and systemic administration. Arzneimittelforschung 1994; 44: 170–7.

106. Pion IA, Koenig KL, Lim HW. Is dermatologic usage of coal tar carcinogenic? A review of the literature. Dermatol Surg 1997; 23: 10–4.

107. Schmid MH, Korting HC. Coal tar, pine tar and sulfonated shale oil preparations: comparative activity, efficacy and safety. Dermatology 1996; 193: 1–5.

108. Schooten FJ van, Godschild R. Coal tar therapy. Is it carcinogenic? Drug Saf 1996; 15: 374–7.

109. Roelofzen JH, Aben KK, Valk PG van der, Houtum JL van, Kerkhof PC van de, Kiemeney LA. Coal tar in dermatology. J Dermatolog Treat 2007; 18: 329–34.

110. Odla S, Vocks E, Rakosji K, Ring J. Successful treatment of dyshidrotic hand eczema using tap water iontophoresis with pulsed direct current. Acta Derm Venereol 1996; 76: 472–4.

111. King CM, Chalmers RJG. A double blind study of superficial radio-therapy in chronic palmar eczema. Br J Dermatol 1984; 111: 445–9.

112. Lindelof B, Wrangsjö K, Lidén S. A double-blind study of Grenz ray therapy in chronic eczema of the hands. Br J Dermatol 1987; 117: 77–80.

113. Warner JA, Cruz PD Jr. Grenz ray therapy in the new millennium: still a valid treatment option? Dermatol 2008; 19: 73–80.

114. Schalock PC, Zug KA, Carter JC, Dhar D, MacKenzie T. Efficacy and patient perception of Grenz ray therapy in the treatment of dermatoses refractory to other medical therapy. Dermatol 2008; 19: 90–4.

115. Kranke B, Szolar-Platzer C, Komoricki P, Derhaschnig J, Aberer W. Epidemiological significance of bufexamac as a frequent and relevant contact sensitizer. Contact Dermatitis 1997; 36: 212–5.

116. Geier J, Fuchs T. Kontakallerien durch Bufexamac. Med Klin 1989; 84: 333–8.

117. Cheng C, Michaels J, Scheinfeld N. Alitretinoin: a comprehensive review. Expert Opin Invest Drugs 2008; 17: 437–43.

118. Ruzicka T, Lynde CW, Jemec GB, Diepgen T, Berth-Jones J, Coenraads PJ et al. Efficacy and safety of oral alitretinoin (9-cis retinoic acid) in patients with severe chronic hand eczema refractory to topical corticosteroids: results of a randomized, double-blind, placebo-controlled multicentre trial. Br J Dermatol 2008; 158: 808–17.

119. Paulden M, Rodgers M, Griffi ths S, Duff ey S, Ingram JR et al. Alitretinoin for the treatment of severe chronic hand eczema. Health Technol Assess 2010; 14 Suppl 1: 39–46.

120. English JS, Woolton CI. Recent advances in the management of hand dermatitis: does alitretinoin work? Clin Dermatol 2011; 29: 273–7.

121. Granlund H, Erkko P, Reitamo S. Comparison of the in/fluence of cyclosporine and topical betamethasone-17,21dipropionate treatment on quality of life in chronic hand eczema. Acta Derm Venereol 1997; 77: 54–8.

122. Granlund H, Erkko P, Reitamo S. Long-term follow-up of eczema patients treated with cyclosporine. Acta Derm Venereol 1998; 78: 40–3.

123. Alexandroff AB, Johnston GA. Medical management of contact dermatitis. G Ital Dermatol Venereol 2009; 144: 537–40.

124. Schram ME, Borgonjen RJ, Bik CM, Schroeff JG van der, Everdingen JJ van, Spuls PI. Off-Label Working and Project Group of Dutch Society of Dermatology and Venereology. Off-label use of azathioprine in dermatology: a systematic review. Arch Dermatol 2011; 147: 474–88.

125. Lodén M. Barrier recovery and in/fluence of irritant stimuli in skin treated with a moisturizer cream. Contact Dermatitis 1997; 36: 256–60.

126. Zhao H, Mailbach HJ. Moisturizers in preventing irritant contact dermatitis: an overview. Contact Dermatitis 1998; 38: 241–4.

127. Lynde CW. Moisturizers: what they are and how they work. Skin Therapy Lett 2001; 6: 3–5.

128. Agner T, Held E. Skin protection programmes. Contact Dermatitis 2002; 47: 253–6.

129. Kutting B, Drexler H. Effectiveness of skin protection creams as a preventive measure in occupational dermatitis: a critical update to criteria of evidence-based medicine. Int Arch Occup Environ Health 2003; 76: 253–6.
water gradients and hydration in vivo. Br J Dermatol 2008; 159: 567–77
131. Diepgen TL, Svensson A, Coenraads PJ. Therapie von Handekzemen. Was können wir von publizierten klinischen Studien lernen? Hautarzt 2005; 56: 224–31
132. Skudlik C, Breuer K, Jünger M, Allmers H, Brandenburg S, John SM. Optimierte Versorgung von Patienten mit berufsbedingten Handekzemen – Hautarztverfahren und Stufenverfahren Haut der gesetzlichen Unfallversicherung. Hautarzt 2008; 59: 690–5
133. John SM, Wehrmann W. Hautkrankheiten. In: Fritze J, Mehrhoff F, Hrsg. Die ärztliche Begutachtung. Rechtsfragen, Funktionsprüfungen, Beurteilungen. Heidelberg: Springer, 2012. 8. Aufl. S. 473–96